Truth Frequency Radio


Apr 28, 2013

 Researchers have abruptly halted a trial of an experimental “AIDS vaccine” after 14 people were infected as a result.

HIV_9by Chris and Sheree Geo

Truth Frequency Radio

Update: Information has been brought to light that the volunteers were told that this vaccine WAS to “prevent AIDS”, which directly contradicts the purpose of the study, as stated by the University.

proof they lied

According to the LA Times, the investigators involved in recruitment (mostly of gay and transgendered males) and experimentation with the genetically-engineered “HVTN 505” after 14 “participants” actually acquired the virus during the trials. They actually admit in their own documents that people were inevitably going to be infected either way, the only reason they did the study was to see if it could “lower the viral load” of the ones that did get it, and that the only reason they are stopping the study is because more people became infected after getting the vaccine than the placebo. The investigators were also ordered to inform all of the nearly 2,500 people who received the “vaccine” of the “mistake”.

“Where were these volunteers?”, you ask. Nambia? Nope. The Congo? Nope. Some sad little Southeast Asian dump we left behind in some post-war hell 30 years ago? Nope. These studies,  sponsored by the National Institute for Allergy and Infectious Diseases (NIAID) and the HIV Vaccine Trials Network, happened right here in America. 

From the NIAID’s Q & A page:

When launched in 2009, the study’s main goal was to test whether the vaccine regimen could reduce the amount of HIV in the blood (viral load) of vaccinated people who later became infected with the virus….

The study was not intended to lead to the licensure of the vaccine regimen being tested, but rather to answer important scientific questions that could lead to the discovery and development of new and improved HIV vaccines in the future….

During a scheduled interim review of the study’s data on April 22, 2013, an independent data and safety monitoring board (DSMB) found that the vaccine regimen did not prevent HIV infection nor reduce viral load among vaccine recipients who became infected with HIV. As a result, the DSMB recommended that no further vaccinations with the investigational regimen be administered. NIAID concurred with this recommendation….

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, sponsored the HVTN 505 study. The NIAID-supported HIV Vaccine Trials Network (HVTN) conducted the clinical trial. NIAID’s Dale and Betty Bumpers Vaccine Research Center (VRC) developed the two investigational vaccines that were being studied.

The study was led by co-chairs Scott M. Hammer, M.D., professor of medicine and chief, division of infectious diseases at Columbia University Medical Center, New York, and Magdalena Sobieszczyk, M.D., assistant professor of clinical medicine at Columbia University Medical Center….

The HVTN 505 vaccine regimen consisted of a series of three immunizations over the course of eight weeks with a recombinant DNA-based vaccine (the priming vaccine). The DNA priming vaccine (called VRC-HIVDNA016-00-VP) contained genetic material expressing antigens representing proteins from both the surface and internal structures of HIV. Following completion of the series of three immunizations with the priming vaccine, vaccine recipients received a single immunization in week 24 with a recombinant vaccine (the boosting vaccine) based on a weakened adenovirus type 5 (Ad5) to carry the genetic material expressing a matching set of HIV antigens to stimulate the immune system. Adenoviruses are common viruses that normally cause colds, but the Ad5 virus used in the HVTN 505 study’s vaccine regimen had been disabled so that it could not cause a cold or other respiratory illness.

Neither the DNA-based vaccine nor the Ad5 vaccine could infect study participants with HIV. Both vaccines had previously been given to hundreds of people in earlier clinical trials. No one had acquired HIV infection through immunizations with either vaccine because they both lack many of the pieces of the virus that are required to cause infection. Unlike other vaccines, such as those designed to combat influenza, these investigational HIV vaccines are not made from live, killed or attenuated (weakened) HIV. Therefore, it is impossible to acquire HIV infection or develop AIDS from the vaccines….

The HVTN 505 study team enrolled 2,504 HIV-negative men who have sex with men and transgender people who have sex with men. The volunteers were 18 to 50 years old and lived in the United States. The study required that all male volunteers at time of enrollment be circumcised and all participants be free of antibodies to the Ad5 common cold virus. The circumcision and Ad5 requirements were implemented in light of an HIV vaccine clinical trial, known as the Step Study, which found in 2007 an increased number of HIV infections among vaccine recipients, particularly those who were not circumcised and/or had Ad5 antibodies.

The study was conducted at 21 sites in the following 19 U.S. cities:

  • Annandale, Va.
  • Atlanta, Ga.
  • Aurora, Colo.
  • Bethesda, Md.
  • Birmingham, Ala.
  • Boston, Mass.
  • Chicago, Ill.
  • Cleveland, Ohio
  • Dallas, Texas
  • Decatur, Ga.
  • Houston, Texas
  • Los Angeles, Calif.
  • Orlando, Fla.
  • Nashville, Tenn.
  • New York, N.Y.
  • Philadelphia, Pa.
  • Rochester, N.Y.
  • San Francisco, Calif.
  • Seattle, Wash.

 

(If someone you know uses Backpages or Craigslist Personals for a little fun on the weekends, they might want to know about this. Just because it’s not the late-80’s anymore doesn’t mean those horrific days can’t be resurrected, especially if this virus has been genetically altered.)

 

Additionally, an independent data and safety monitoring board (DSMB) composed of clinical research experts, statisticians, ethicists and community representatives conducted regularly scheduled interim analyses of HVTN 505’s clinical data. Furthermore, new HIV infections were monitored  as they were diagnosed to keep the closest possible watch on the safety of the study participants. The DSMB met 8 times to review the HVTN 505 study data since the trial’s 2009 launch.

Each HVTN 505 study participant received the best available HIV prevention services, including risk-reduction assessments, counseling on how to avoid HIV exposure, free condoms, and guidance on how to access HIV prevention services in the local community.

HVTN 505’s enrollment criteria also were designed to protect the study participants because the Ad5 vaccine is similar but distinct from the Ad5 vaccine evaluated in an HIV vaccine study known as Step (Statement: Immunizations Are Discontinued in Two HIV Vaccine Trials). Specifically, the study was limited to men in the United States who have sex with men who were circumcised and who did not have Ad5 antibodies at time of enrollment. This requirement was in place because there were more HIV infections among male vaccine recipients in the Step study who were not circumcised and who had Ad5 antibodies at enrollment than among those participants with the same characteristics who received the placebo injection. Conversely, Step vaccine recipients who were circumcised and without Ad5 antibodies at enrollment had similar rates of HIV infection to those who received the placebo vaccine….

During its scheduled interim review, the HVTN 505 DSMB found that the investigational vaccine regimen neither prevented HIV infection nor reduced viral load among vaccine recipients who later became infected with the virus. The DSMB examined information gathered from 1,250 volunteers who received the investigational vaccine regimen and 1,244 volunteers who received the placebo vaccine. The primary analysis looked at volunteers who were diagnosed with HIV infection after having been in the study a minimum of 28 weeks. This was done to enable enough time for the vaccine regimen to be given and stimulate an immune response. In this analysis, 27 HIV infections occurred among the vaccine recipients, and 21 HIV infections occurred among the placebo vaccine recipients. Among volunteers who became HIV-infected during the first 28 weeks of the study, 14 cases of HIV infection occurred among those who received the investigational vaccine regimen, and 9 HIV infections occurred among the placebo vaccine recipients.

In addition, the DSMB found that the vaccine failed to reduce viral load among 30 volunteers (15 vaccine recipients and15 placebo recipients) who acquired HIV infection at least 28 weeks after entering the study and who had 20 weeks of viral load data that could be evaluated.

Based on these findings, the DSMB recommended that no further injections of the investigational vaccine regimen be administered. As the trial’s sponsor, NIAID concurred with the DSMB’s recommendation and instructed all HVTN 505 study sites to immediately cease administering injections but continue follow-up with study participants and further evaluate the trial data.

There was a non-statistically significant increase in the number of HIV infections among volunteers in the investigational vaccine group compared to the placebo group. It is not clear why this happened. Based on the finding, the DSMB recommended closer follow-up of participants beyond their month 24 study visit. NIAID agreed, and with the study investigators will be amending the study protocol to allow for closer, extended follow up of the vaccine recipients.


The study investigators are contacting all participants to inform them of the DSMB’s findings and NIAID’s decision to halt injections. Study volunteers are being asked to report to their specific clinic sites over the next few weeks to find out whether they received the investigational vaccines or placebo injections. The study investigators will continue following each participant for five years after their enrollment in the trial.

Individuals who became HIV-infected during the trial have been referred to local health services for appropriate care and treatment. (See question 12.)

The study teams at each site in the 19 cities where HVTN 505 was conducted have ensured that participants who acquired HIV infection during the study obtained access to the highest quality of medical care and HIV treatment available in their communities.

This is the fourth big vaccine trial since 1983, when “AIDS” first arrived.

Flashback: 2009: The Thailand AIDS vaccine study

The results were modest, at best: a 30% reduction rate which Fauci of the NIAID touted as a “success” . Later, the Wall Street Journal broke the story that the positive results of the study were overstated.

 

Flashback: 2007 – Merck’s AIDSVAX study

In 2007, Merck & Co. stopped a study of its experimental vaccine after seeing it did not prevent HIV infection. Later analysis suggested the vaccine might even raise the risk of infection in certain men. Of course, as Yahoo News was quick to point out, “the vaccine did not cause the infection.”)

“One puzzling result — those who became infected had as much virus in their blood whether they got the vaccine or a placebo”

 – New York Times

 

ccFlashback: 1978

The CDC begins experimental hepatitis B vaccine trials in New York. Its advertisements for research subjects specifically ask for promiscuous homosexual men. Professor Wolf Szmuness of the Columbia University School of Public Health had made the vaccine’s infective serum from the pooled blood serum of hepatitis-infected homosexuals and then developed it in chimpanzees, the only animal susceptible to hepatitis B, leading to the theory that HIV originated in chimpanzees before being transferred over to humans via this vaccine. A few months after 1,083 homosexual men receive the vaccine, New York physicians begin noticing cases of Kaposi’s sarcoma, Mycoplasma penetrans and a new strain of herpes virus among New York’s homosexual community — diseases not usually seen among young, American men, but that would later be known as common opportunistic diseases associated with AIDS (Goliszek).

The experimental hepatitis B vaccine injected into gays was unlike any other vaccine previously made. It was developed in chimpanzees and manufactured in a year-long process of sterilization and purification of the pooled blood of 30 gay men who were hepatitis B virus carriers. During the first gay experiment (November 1978-October 1979) at the New York Blood Center, there was great concern that the vaccine might be contaminated. According to June Goodfield’s Quest for the Killers, p 86, “This was no theoretical fear, contamination having been suspected in one batch made by the National Institutes of Health, though never in Merck’s.” The men were given three inoculations of the vaccine over a period of time. The vaccine was successful with 96% of the men developing protective antibodies against the hepatitis B virus.

hepbIt has been assumed by some that these men were immunosuppressed due to their promiscuity and history of venereal disease. Although the young men in the study were indeed “promiscuous” (this was a requirement for entrance into the study), they were in excellent health. Despite many previous sexual partners, these volunteers had never contracted evidence of hepatitis B infection. Furthermore, immunosuppressed people often do not respond to the vaccine.

The men in the Manhattan experiment had the highest rate of HIV ever recorded for that time period (over 20% of the men were HIV-positive in 1981, and over 40% in 1984). Therefore, it must be assumed that many, if not most, of these men eventually died of AIDS. The actual number of AIDS deaths among the men in the experiment has never been revealed, nor have their medical records been studied. Attempts to secure this information have been rebuffed due to the “confidential” nature of the experiment.

Screenshot_2

It would seem that Columbia University has some explaining to do. The odds are too coincidental that they could have fomented a new mutated form of HIV just 30 years after one of their viral vaccines helped create AIDS.

Sheree will update the story more after the show today. Be sure to tune in to listen to what Douglas Dietrich has to offer as a former military librarian with insider knowledge on biological warfare.

Sources:

http://articles.latimes.com/2013/apr/26/science/la-sci-hiv-vaccine-trial-halted-20130426

http://www.whale.to/b/cantwell9.html#The_gay_hepatitis_B_experiments_%281978-1981%29_

http://www.niaid.nih.gov/news/QA/Pages/HVTN505qa2013.aspx

http://www.niaid.nih.gov/news/newsreleases/2009/Pages/ThaiVaxStudy.aspx

http://www.hvtn.org/media/pr/HVTN505studyflyerFINALV1.pdf

http://news.yahoo.com/s/ap/20090924/ap_on_re_as/med_aids_vaccine

http://health.usnews.com/articles/health/infectious-diseases/2009/10/20/health-buzz-aids-vaccine-results-deemed-modest-and-other-health-news.html

http://online.wsj.com/article/SB125603405226896225.html?mod=googlenews_wsj

2013-04-28_0903

Read more articles by this author HERE.

Chris & Sheree Geo founded Truth Frequency Radio with the purpose of compiling an archive of information which can be used for generations to come. Not your typical radio show, Truth Frequency focuses more on the history of the occult and the deeper underlying conspiracy behind current events in an effort to predict the future by understanding the past. Chris & Sheree are not only researchers into the occult and esoteric but have also produced the musical album Global Resistance which is a mixture of rock, techno and hip hop with conscious lyrics exposing the New World Order.

MORE NEWS BY NEWS >>